Compare RLI & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLI | BLCO |
|---|---|---|
| Founded | 1965 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.1B |
| IPO Year | 1994 | 2022 |
| Metric | RLI | BLCO |
|---|---|---|
| Price | $59.48 | $16.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $62.40 | $18.45 |
| AVG Volume (30 Days) | ★ 506.2K | 373.5K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.16% | N/A |
| EPS Growth | ★ 16.84 | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | $1,882,448,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $8.65 |
| Revenue Next Year | $3.53 | $5.59 |
| P/E Ratio | $24.97 | ★ N/A |
| Revenue Growth | 6.33 | ★ 6.47 |
| 52 Week Low | $47.26 | $13.77 |
| 52 Week High | $67.12 | $18.92 |
| Indicator | RLI | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 44.07 |
| Support Level | $58.08 | $16.84 |
| Resistance Level | $63.41 | $17.20 |
| Average True Range (ATR) | 1.17 | 0.48 |
| MACD | -0.39 | -0.13 |
| Stochastic Oscillator | 16.69 | 17.69 |
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety, and it derives a majority of its revenue from the Casualty segment.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.